Anteris Technologies selected to showcase transcatheter heart valve at TVT 2021 ‘Call For Innovation’

Anteris Technologies Ltd’s (ASX:AVR) transcatheter heart valve has been handpicked for a presentation at the Transcatheter Valve Therapies (TVT) Structural Heart Summit next month. The ASX-lister will facilitate a presentation at the summit’s ‘The Call For Innovation’ segment, focused on its 3D single-piece DurAVR™ THV heart valve. During the presentation, the company intends to expand on the heart valve’s innovative qualities, the benefits it brings to patients and ways it “lasts longer and works better” than devices currently available. Interventional Cardiologist at the Minneapolis Heart Institute at the Abbott Northwestern Hospital, Dr Paul Sorajja MD, PhD, will present Anteris’ heart valve at the summit. The summit kicks off on July 20 from Miami Beach, Florida, and runs for three days. “DurAVR™ will be a major market entrant”: CEO Anteris CEO Wayne Paterson said: “Once again DurAVR™ has been acknowledged by the medical community for being highly innovative. “As we continue to advance our program and gain prestigious recognition such as being accepted for this presentation, we are increasingly confident that DurAVR™ will be a major market entrant into the global TAVR market. “The evidence is compelling that the DurAVR™ THV System will meet the needs for lifetime management of aortic stenosis patients by lasting the lifetime of the patient and will provide physicians with a solution that goes beyond the current products in the market, which is essential in younger and more active patients.” Dr Sorajja echoed the CEO’s comments and said: “The DurAVR™ THV system uniquely combines three highly novel technologies - ADAPT® anti-calcification technology, a single piece heart valve (DurAVR™), and commissure alignment that is an inherent design for transfemoral delivery (ComASUR™).” The Structural Heart Summit Each year, the Cardiovascular Research Foundation and the Transcatheter Valve Therapies’ Structural Heart Summit convenes leaders in the field to present three days of groundbreaking clinical and scientific information. The congress also features expertly developed series in these spaces, plus late-breaking clinical science, challenging cases and connection to a community of thought leaders from across the globe. ‘The Call For Innovation’ is a high profile component of the meeting and regarded as the pre-eminent forum for the introduction of new technologies that have the potential to make a significant impact within the field. Anteris says the selection process for the presentation is highly competitive, drawing submissions from large and small companies alike in the TAVR, mitral, tricuspid and left arterial appendage closure spaces. The summit’s innovation sessions are keenly watched by key opinion leaders, high-level industry executives and regulators from around the world, such as the Food and Drug Administration. Series of cash injections Today’s announcement comes just weeks after the ASX-listed structural heart company boosted its bottom line with a $1.49 million research & development refund. Anteris received the repayment under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme and used the capital to repay a short-term funding facility with Mitchell Asset Management Pty Ltd. Just one week prior to that, Anteris secured $2.3 million through a placement. The cash injection was predominantly supported by Anteris’ existing top 10 institutional shareholders, with more than 300,000 new ordinary shares distributed at $7.50 apiece. Placement investors also received one unlisted two-year option, exercisable at $11.50, for every two new shares issued. Funds from the equity raise were earmarked as additional working capital facilities.